Excipients in parenteral formulations: selection considerations and effective utilization with small molecules and biologics

References

• Pifferi G, Restani P. The safety of pharmaceutical excipients. Farmaco. 2003;58:541–550.
   PubMedGoogle Scholar
• Cobert B. Excipients and inactive ingredients in drugs & drug safety, C3IHC Blog, 2014.
   Google Scholar
• Apte SP, Ugwu SO. A review and classification of emerging excipients in parenteral medications. Pharm Technol. 2003; 27:46–60.
   Google Scholar
• Chaudhari SP, Patil PS. Pharmaceutical excipients: a review. Int J Adv Pharm Biol Chem. 2012;1:21–34.
   Google Scholar
• Qualifications of Excipients for Pharmaceutical Use, International Pharmaceutical Excipients Council, 2008.
   Google Scholar
• Abrantes CG, Duarte D, Reis CP. An overview of pharmaceutical excipients: safe or not safe? J Pharm Sci. 2016;105:2019–2026.
   PubMed Web of Science ®Google Scholar
• Chang R-K, Chang D. Review of current issues in pharmaceutical excipients. 2006;31.
   Google Scholar
• Medi MB, Chintala R, Bhambhani A. Excipient selection in biologics and vaccines formulation development. Eur Pharm Rev. 1998;6:S21–S20.
   Google Scholar
• Faqi AS, editor. A comprehensive guide to toxicology in preclinical drug development. Cambridge (MA): Academic Press; 2012.
   Google Scholar
• Mohan C. Calbiochem^® Buffers – A guide for the Preparation of Buffers in Biological Systems. 2006.
   Google Scholar
• Joyce MA, Leonore C. Witchey-Lakshmanan. Sterile Product Development, AAPS Advances in the Pharmaceutical Sciences Series 6. 2013.
   Google Scholar
• Rowe R, Sheskey P, Quinn M. Handbook of Pharmaceutical Excipients, 6th ed. London, UK: Pharmaceutical Press; 2009.
   Google Scholar
• Farkas E, Ryadnov M. Amino Acid, Peptides, and Proteins, Vol 37. Cambridge, UK: The Royal Society of Chemistry; 2012.
   Google Scholar
• Watters D, Watters J. Approaches to learning by students in the biological sciences: implications for teaching. Int J Sci Educ. 2007;29:19.
   Web of Science ®Google Scholar
• Barr-David F. Preparation of buffers for us in enzyme studies. AIChE J. 1955;1:415–416.
   Google Scholar
• Alvaran S. Serum Osmolality. 2015.
   Google Scholar
• Loftsson T. Drug stability for pharmaceutical scientists: Chapter 3 – Degradation Pathways. Cambridge, UK: Academic Press; 2014.
   Google Scholar
• Elder D, Crowley P. Antimicrobial preservatives part two: choosing a preservative. Am Pharm Rev. 2012.
   Google Scholar
• Unger EC, Shen D, Wu G, et al. Gadolinium-containing co-polymeric chelates-a new potential MR contrast agent. Magma. 1999;8:154–162.
   PubMedGoogle Scholar
• Food and Drug Administration: Inactive Ingredient Database Available from: https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm.
   Google Scholar
• Prasad N, Straus D, Reichart G. inventors; Nestec SA, assignee. Cyclodextrin flavor delivery systems. United States patent US 6,287,603. 2001
   Google Scholar
• Editors. Sustained-Release Injectable Drug Delivery: A review on the current status of long-acting injectables, including commercially marketed products, Pharmaceutical Technology, Vol. 2010; 2010.
   Google Scholar
• Kulshreshtha AK, Singh ON, Wall GM. Pharmaceutical Suspensions: From Formulation Development to Manufacturing.
   Google Scholar
• Pramanick S, Chandel V, Singodia D. Excipient selection in parenteral formulation development. Pharma Times 2013;45:65–77.
   Google Scholar
• Katragadda U, Teng Q, Rayaprolu BM, et al. Multi-drug delivery to tumor cells via micellar nanocarriers. Int J Pharm. 2011;419:281–286.
   PubMed Web of Science ®Google Scholar
• Rayaprolu BM, Strom JG. Design and evaluation of D-α tocopheryl polyethylene glycol 1000 succinate emulsified poly-ϵ-caprolactone nanoparticles for protein/peptide drug delivery. Drug Dev Ind Pharm. 2013;39:1046–1052.
   PubMed Web of Science ®Google Scholar
• Chi EY, Krishnan S, Randolph TW, et al. Physical stability of proteins in aqueous solution: mechanism and driving forces in nonnative aggregation. Pharm Res. 2003;20:1325–1336.
   PubMed Web of Science ®Google Scholar
• Kamerzell TJ, Esfandiary R, Joshi SB, et al. Protein-excipient interactions: mechanisms and biophysical characterization applied to protein formulation development. Adv Drug Deliv Rev. 2011;63:1118–1159.
   PubMed Web of Science ®Google Scholar
• Ohtake S, Kita Y, Arakawa T. Interactions of formulation excipients with proteins in solution and in the dried state. Adv Drug Deliv Rev. 2011;63:1053–1073.
   PubMed Web of Science ®Google Scholar
• Challener CA. Excipients selection for protein stabilization. Pharm Technol 2015;2015:35–39.
   Google Scholar
• HR, DesuSunil, T. Narishetty. Challenges in freeze-thaw processing of bulk protein solutions, Sterile Product Development. 2008. pp. 167–203.
   Google Scholar
• Jennings TA. Effect of formulation on lyophilization, part 1. IVD Technology Magazine. 1997
   Google Scholar
• Constantino HR. Excipients for use in lyophilized pharmaceutical peptide, protein and other bioproducts. Lyophili Biopharm. AAPS press. pp. 139–228. 2004.
   Google Scholar
• Mehmood Y, Farooq U. Excipients use in parenteral and lyophilized formulation development. J Pharm Pharmacol 2015;3:19–27.
   Google Scholar
• Fathima N, Mamatha T, Kanwal Qureshi H, et al. Drug-excipient interaction and its importance in dosage form development. J Appl Pharm Sci 2011;01:66–71.
   Google Scholar
• Hirakura Y, Nakamura M, Wakasawa T, et al. Excipient hydrolysis and ester formation increase pH in a parenteral solution over aging. Int J Pharm. 2006;325:26–38.
   PubMed Web of Science ®Google Scholar
• Abend AM, Chung L, Bibart RT, et al. Concerning the stability of benzyl alcohol: formation of benzaldehyde dibenzyl acetate under aerobic conditions. J Pharm Biomed Anal. 2004;34:957–962.
   PubMed Web of Science ®Google Scholar
• Janicki C. Reaction of Haloperidol with 5-(Hydroxymethyl)-2-furfuraldehyde, an impurity in anhydrous lactose. J Pharm Sci. 1974;63:41–43.
   PubMedGoogle Scholar
• Kumar Hotha K, Roy chowdhury S, Subramanian V. Drug-excipient interactions: case studies and overview of drug degradation pathways. Ajac. 2016;7:107.
   Google Scholar
• Elder DP, Kuentz M, Hol R. Pharmaceutical Excipients- quality, regulatory and biopharmaceutical considerations. Eur J Pharm Sci. 2016;87:88–99.
   PubMed Web of Science ®Google Scholar
• Guidance for Industry- Nonclinical Studies for the Safety Evaluation of Pharmaceutical Excipients, U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Pharmacology/Toxicology. 2005. Available from: https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM079250.pdf
   Google Scholar